logo
The Hunt for a Fundamental Theory of Quantum Gravity

The Hunt for a Fundamental Theory of Quantum Gravity

WIRED2 days ago
Jul 20, 2025 7:00 AM Black hole and Big Bang singularities break our best theory of gravity. A trilogy of theorems hints that physicists must go to the ends of space and time to find a fix. ILLUSTRATION: MARK BELAN FOR QUANTA MAGAZINE
The original version of this story appeared in Quanta Magazine .
Two blind spots torture physicists: the birth of the universe and the center of a black hole. The former may feel like a moment in time and the latter a point in space, but in both cases the normally interwoven threads of space and time seem to stop short. These mysterious points are known as singularities.
Singularities are predictions of Albert Einstein's general theory of relativity. According to this theory, clumps of matter or energy curve the space-time fabric toward themselves, and this curvature induces the force of gravity. Pack enough stuff into a small enough spot, and Einstein's equations seem to predict that space-time will curve infinitely steeply there, such that gravity grows infinitely strong.
Most physicists don't believe, however, that Einstein's theory says much about what really happens at these points. Rather, singularities are widely seen as 'mathematical artifacts,' as Hong Liu, a physicist at the Massachusetts Institute of Technology, put it, not objects that 'occur in any physical universe.' They are where general relativity malfunctions. The singularities are expected to vanish in a more fundamental theory of gravity that Einstein's space-time picture merely approximates—a theory of quantum gravity.
But as physicists take steps toward that truer and more complete theory by merging general relativity and quantum physics, singularities are proving hard to erase. The British mathematical physicist Roger Penrose won the Nobel Prize in Physics for proving in the 1960s that singularities would inevitably occur in an empty universe made up entirely of space-time. More recent research has extended this insight into more realistic circumstances. One paper established that a universe with quantum particles would also feature singularities, although it only considered the case where the particles don't bend the space-time fabric at all. Then, earlier this year, a physicist proved that these blemishes exist even in theoretical universes where quantum particles do slightly nudge space-time itself—that is, universes quite a bit like our own.
This trilogy of proofs challenges physicists to confront the possibility that singularities may be more than mere mathematical mirages. They hint that our universe may in fact contain points where space-time frays so much that it becomes unrecognizable. No object can pass, and clocks tick to a halt. The singularity theorems invite researchers to grapple with the nature of these points and pursue a more fundamental theory that can clarify what might continue if time truly stops. Space-Time's Fatal Flaws
Karl Schwarzschild first discovered an arrangement of space-time with a singularity in 1916, just months after Einstein published general relativity. The bizarre features of the 'Schwarzschild solution' took years for physicists to understand. Space-time assumes a shape analogous to a whirlpool with walls that swirl more and more steeply as you go farther in; at the bottom, the curvature of space-time is infinite. The vortex is inescapable; it has a spherical boundary that traps anything falling inside, even light rays.
It took decades for physicists to accept that these inconceivable objects, eventually dubbed black holes, might actually exist. The British mathematical physicist Roger Penrose proved that given two simple assumptions, space-time must end at points called singularities. COURTESY OF PUBLIC DOMAIN
J. Robert Oppenheimer and Hartland Snyder calculated in 1939 that if a perfectly spherical star gravitationally collapses to a point, its matter will become so dense that it will stretch space-time into a singularity. But real stars bubble and churn, especially while imploding, so physicists wondered whether their nonspherical shapes would stop them from forming singularities.
Penrose eliminated the need for geometric perfection in 1965. His landmark proof relied on two assumptions. First, you need a 'trapped surface' inside of which light can never escape. If you cover this surface in light bulbs and switch them on, their light rays will fall inward faster than they can travel outward. Crucially, this shell of light will shrink regardless of whether it started out as a perfect sphere, a dimpled golf ball, or something more misshapen.
Second, space-time should always curve in such a way that light rays bend toward each other but never diverge. In short, gravity should be attractive, which is the case so long as energy is never negative.
With these two stipulations, Penrose proved the mortality of at least one of the trapped light rays. Its otherwise eternal journey through space and time must terminate in a singularity, a point where the space-time fabric ceases to exist, where there is no future for the light ray to travel into. This was a new definition of a singularity, distinct from the infinite curvature of the Schwarzschild solution. Its generality enabled Penrose to prove in three scant pages of math that, under his two assumptions, singularities will inevitably form. Caption: A hand-drawn figure in Penrose's 1965 paper proving the singularity theorem shows the collapse of space-time to form a singularity. The paper has been called 'the most important paper in general relativity' since Einstein's. ILLUSTRATION: Roger Penrose, Physical Review Letters, American Physical Society
'Penrose's paper was probably the most important paper in general relativity ever written, other than Einstein's original paper,' said Geoff Penington, a physicist at the University of California, Berkeley.
Stephen Hawking soon extended Penrose's argument to the early universe, proving that a cosmos described by general relativity must have sprung from a singular point during the Big Bang. This cosmological singularity resembles a black hole in that, if you imagine rewinding the history of the universe, light rays will run into a wall at the beginning of time.
Over the years, physicists have accumulated heaps of evidence that black holes exist, and that the universe began with an event that looks very much like a Big Bang. But do these phenomena truly represent space-time singularities?
Many physicists find the actual existence of such points unthinkable. When you try to calculate the fate of a particle approaching the singularity, general relativity glitches and gives impossible, infinite answers. 'The singularity means a lack of predictability,' Liu said. 'Your theory just breaks down.'
But the particle in the real world must have a fate of some sort. So a more universal theory that can predict that fate—very likely a quantum theory—must take over.
General relativity is a classical theory, meaning that space-time takes on one, and only one, shape at every moment. In contrast, matter is quantum mechanical, meaning it can have multiple possible states at once—a feature known as superposition. Since space-time reacts to the matter in it, theorists expect that any matter particles in a superposition of occupying two different locations should force space-time into a superposition of two distortions. That is, space-time and gravity should also follow quantum rules. But physicists haven't yet worked out what those rules are. Into the Onion
Theorists approach their quest for a quantum theory of gravity the way they might peel an onion: layer by layer. Each layer represents a theory of a universe that imperfectly approximates the real one. The deeper you go, the more of the interplay between quantum matter and space-time you can capture. The German physicist-soldier Karl Schwarzschild calculated the shape that space-time takes around a massive point. Years later, physicists realized that this geometry contains a singularity. COURTESY OF PUBLIC DOMAIN
Penrose worked in the outermost layer of the onion. He used the general theory of relativity and ignored quantumness entirely. In effect, he proved that the space-time fabric has singularities when it is completely devoid of any quantum matter.
Physicists aspire to someday reach the onion's core. In it, they'll find a theory describing both space-time and matter in all their quantum glory. This theory would have no blind spots—all calculations should yield meaningful results.
But what about the middle layers? Could physicists resolve Penrose's singularities by moving to something a little more quantum, and therefore a little more realistic?
'It was the obvious speculation, that somehow quantum effects should fix the singularity,' Penington said.
They first tried to do so in the late 2000s. The assumption that had confined Penrose's proof to the outermost layer was that energy is never negative. That's true in everyday, classical situations, but not in quantum mechanics. Energy goes negative, at least momentarily, in quantum phenomena such as the Casimir effect, where (experiments show) two metal plates attract each other in a vacuum. And negative energies play a role in the way black holes are thought to radiate particles, eventually 'evaporating' entirely. All the deeper, quantum layers of the onion would feature this exotic energetic behavior.
The physicist who peeled the top layer was Aron Wall, then based at the University of Maryland and now at the University of Cambridge. To cut into the quantum realm and abandon Penrose's energy assumption, Wall latched on to a theoretical discovery made in the 1970s by Jacob Bekenstein.
Bekenstein knew that for any given region of space, the contents of the region grow more mixed up as time goes on. In other words, entropy, a measure of this mixing, tends to increase, a rule known as the second law of thermodynamics. While considering a region that contains a black hole, the physicist realized that the entropy comes from two sources. There's the standard source—the number of ways that quantum particles in the space around the black hole could be arranged. But the black hole has entropy too, and the amount depends on the black hole's surface area. So the total entropy of the region is a sum: the surface area of the black hole plus the entropy of nearby quantum stuff. This observation became known as the 'generalized' second law.
Wall 'made it his mission to understand the generalized second law,' said Raphael Bousso, a physicist at Berkeley. 'He was thinking about it in much clearer and much better ways than everybody else on the planet.'
Reaching the quantum layers of the onion would mean accommodating negative energy and the presence of quantum particles. To do so, Wall reasoned that he could take any surface area in general relativity and add to it the entropy of those particles, as the generalized second law suggested. Penrose's proof of his singularity theorem had involved the trapped surface. So Wall upgraded it to a 'quantum trapped surface.' And when he reworked Penrose's singularity theorem in this way, it held. Singularities form even in the presence of quantum particles. Wall published his findings in 2010. In 2010, Aron Wall, now at the University of Cambridge, revamped Penrose's proof to show that singularities exist in a world where space-time has no quantum properties but is filled with particles that do. PHOTOGRAPH: NICOLE WALL
'Aron's paper was a seminal breakthrough in combining quantum mechanics and gravity in a more precise way,' Penington said.
Having peeled back the classical outer layer of the onion, where energy is always positive, Wall reached a lightly quantum layer—a context physicists call semiclassical. In a semiclassical world, space-time guides the journeys of quantum particles, but it cannot react to their presence. A semiclassical black hole will radiate particles, for instance, since that's a consequence of how particles experience a space-time warped into a black hole shape. But the space-time—the black hole itself—will never actually shrink in size even as the radiation leaks energy into the void for all eternity.
That's almost, but not exactly, what happens in the real universe. You could watch a black hole radiate particles for a century without seeing it shrink a single nanometer. But if you could watch for longer—many trillions upon trillions of years—you would see the black hole waste away to nothing.
The next onion layer beckoned. Dialing Up the Quantumness
Bousso recently revisited Wall's proof and found that he could cut a little deeper. What about the world where black holes shrink as they radiate? In this scenario, the space-time fabric can react to quantum particles.
Using more refined mathematical machinery developed by Wall and others since 2010, Bousso found that, despite the intensified quantumness of his scenario, singularities continue to exist. He posted his paper, which has not yet been peer-reviewed, in January.
The world of Bousso's new theorem still departs from our universe in notable ways. For mathematical convenience, he assumed that there's an unlimited variety of particles—an unrealistic assumption that makes some physicists wonder whether this third layer matches reality (with its 17 or so known particles) any better than the second layer does. 'We don't have an infinite number of quantum fields,' said Edgar Shaghoulian, a physicist at the University of California, Santa Cruz.
Still, for some experts, Bousso's work delivers a satisfying denouement to the Penrose and Wall singularity story, despite its unrealistic abundance of particles. It establishes that singularities can't be avoided, even in space-times with mild reactions to quantum matter. 'Just by adding small quantum corrections, you can't prevent the singularity,' Penington said. Wall and Bousso's work 'answers that pretty definitively.' The Real Singularity
But Bousso's theorem still doesn't guarantee that singularities must form in our universe.
Some physicists hold out hope that the dead ends do somehow go away. What seems like a singularity could actually connect to somewhere else. In the case of a black hole, perhaps those light rays end up in another universe.
And a lack of a Big Bang singularity might imply that our universe began with a 'Big Bounce.' The idea is that a previous universe, as it collapsed under the pull of gravity, somehow dodged the formation of a singularity and instead bounced into a period of expansion. Physicists who are developing bounce theories often work in the second layer of the onion, using semiclassical physics that exploits negative-energy quantum effects to get around the singularity required by the Penrose and Hawking theorems. In light of the newer theorems, they will now need to swallow the uncomfortable truth that their theories violate the generalized second law as well.
One physicist pursuing bounces, Surjeet Rajendran of Johns Hopkins University, says he is undaunted. He points out that not even the generalized second law is gospel truth. Rejecting it would make singularities avoidable and continuations of space-time possible.
Singularity skeptics can also appeal to the theory at the core of the onion, where space-time behaves in truly quantum ways, such as taking on superpositions. There, nothing can be taken for granted. It becomes hard to define the concept of area, for instance, so it's not clear what form the second law should take, and therefore the new theorems won't hold.
Bousso and like-minded physicists, however, suspect that a highly quantum arena with no notion of area is tantamount to a dead-end for a light ray, and therefore that something Penrose would recognize as a singularity should persist in the core theory and in our universe. The beginning of the cosmos and the hearts of black holes would truly mark edges of the map where clocks can't tick and space stops.
'Inside of black holes, I am positive there is some notion of singularity,' said Netta Engelhardt, a physicist at MIT who has worked with Wall.
In that case, the still-unknown fundamental theory of quantum gravity would not kill singularities but demystify them. This truer theory would allow physicists to ask questions and calculate meaningful answers, but the language of those questions and answers would change dramatically. Space-time quantities like position, curvature and duration might be useless for describing a singularity. There, where time ends, other quantities or concepts might have to take their place. 'If you had to make me guess,' Penington said, 'whatever quantum state describes the singularity itself does not have a notion of time.'
Original story reprinted with permission from Quanta Magazine, an editorially independent publication of the Simons Foundation whose mission is to enhance public understanding of science by covering research developments and trends in mathematics and the physical and life sciences.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

Yahoo

time22 minutes ago

  • Yahoo

Senti Biosciences Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

– Video webcast now available on-demand SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ('Senti Bio'), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Senti Bio Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company's wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti's Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships. Availability of Other Information About Senti Biosciences, Inc. For more information, please visit the Senti Bio website at or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website ( including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775SNTI@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Moleculin Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Moleculin Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

Yahoo

time22 minutes ago

  • Yahoo

Moleculin Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference

– Video webcast now available on-demand HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Founder, President, CEO and Chairman of Moleculin, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the segment, Mr. Klemp dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page of the Investors section of the Company's website ( About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775MBRX@ in to access your portfolio

Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

Yahoo

timean hour ago

  • Yahoo

Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

MarketNewsUpdates News Commentary NEW YORK, July 22, 2025 /CNW/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth. The report said: "In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market growth further. The increasing prevalence of eye-related conditions, such as diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma, is a significant factor driving the adoption of AI in ophthalmology. As the population ages, the incidence of these diseases increases, creating a need for efficient and accurate diagnostic tools. For instance, according to the CDC, the estimated number of Americans living with glaucoma in 2022 was 4.22 million. AI algorithms can rapidly analyze complex retinal images, facilitating early detection and treatment. For instance, AI systems have shown high sensitivity and specificity in identifying diabetic retinopathy, which allows for timely interventions and reduces the risk of vision loss. Moreover, integrating advanced imaging techniques such as Optical Coherence Tomography (OCT) with AI has revolutionized ophthalmic diagnostics. High-resolution imaging provides detailed views of ocular structures, which enhances diagnostic precision when analyzed by artificial intelligence (AI). The availability of large datasets from these imaging technologies allows for the training of robust AI models, improving their accuracy and reliability in clinical settings." Active healthcare/tech companies active in the diabetes treatment industry include: Avant Technologies Inc. (OTCQB: AVAI), Alcon Inc. (NYSE: ALC), Bausch + Lomb Corporation (NYSE: BLCO), Johnson & Johnson (NYSE: JNJ), Tempus AI, Inc. (NASDAQ: TEM). Research And Markets continued: "Furthermore, teleophthalmology, the remote delivery of eye care services, has gained traction, especially in underserved regions. AI is crucial in this expansion by enabling automated analysis of retinal images, facilitating remote diagnosis, and reducing the need for in-person consultations. This approach increases access to eye care and optimizes resource utilization in healthcare systems. For instance, in June 2024, C3 Med-Tech, an ophthalmic health tech startup, raised USD 0.23 million to launch AI-enabled, portable eye screening devices. The funding is expected to support telemedicine integration, real-time disease detection, and expansion across India, aiming to reduce avoidable blindness, especially in underserved communities facing a shortage of ophthalmologists. Moreover, AI's ability to analyze and interpret data from Electronic Health Records (EHRs) facilitates personalized treatment plans in ophthalmology. AI predicts disease progression by assessing patient history, genetic information, and imaging data and recommends tailored interventions, further contributing to market growth." Avant Technologies, Inc. (OTCQB: AVAI) Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference - Avant Technologies, Inc. ("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that Vinicio Vargas, Chief Executive Officer (CEO) of Avant's partner, Ainnova Tech, Inc., (Ainnova), was a featured speaker Friday and Saturday at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Cartagena, Colombia. The conference highlighted the latest in scientific advances in treatments for the most common eye diseases, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, while also focusing on strengthening collaboration between industry specialists in Latin America. Ainnova's CEO, Vinicio Vargas, who is also a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, discussed the status of AI and its uses in the industry to improve patient outcomes. Vargas and a host of renowned speakers that included Dr. Laura Velásquez, Dr. Roberto Gallego, Hugo Ocampo, and other ophthalmologists and experts presented the latest tools to transform visual health in the region, reflected on unmet needs, and explained how innovation can help build stronger, accessible, and patient-centered health systems. In Q4 2024, Ainnova entered a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to start a pilot program to combat diabetic retinopathy using Ainnova's AI-powered, cutting-edge technology, Vision AI. The alliance aims at improving access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy. If the program is successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through AAC. AAC has the worldwide licensing rights for Ainnova's technology portfolio, which includes Ainnova's Vision AI platform. CONTINUED… Read this and more news for Avant Technologies at: In other diabetes developments and happenings in the biotech market include: Alcon Inc. (NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, recently announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. "Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us reach this milestone," said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. "We have a long legacy of engaging our customers throughout the research and development process to design bold innovations in ophthalmology. This approval is a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients." Bausch + Lomb Corporation (NYSE: BLCO), a leading global eye health company dedicated to helping people see better to live better, recently launched "Eyes Tell the Story: The Impact of Dry Eye." The campaign aims to educate about dry eye through personal stories, compelling imagery and new survey data, and encourages people with symptoms to speak with their eye doctor to find relief. Eyes Tell the Story builds upon Know Your Dry Eye, an educational campaign launched in 2024 that featured data and insights from the company's first State of Dry Eye survey, which showed the majority of Americans may not know that their eye symptoms are associated with eye dryness, despite the growing prevalence of dry eye. This year's survey, conducted among dry eye sufferers who are using either a prescription treatment or over-the-counter (OTC) product, further supports the need for more patient education and to dispel ongoing misconceptions surrounding dry eye. Johnson & Johnson (NYSE: JNJ) recently launched TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The TECNIS Odyssey IOL was first launched in the US in October 2024. The TECNIS Odyssey IOL is a full vision range intraocular lens (IOL), built on the TECNIS platform from Johnson & Johnson, which, according to the company, provides 2 times better contrast in low lighting than PanOptix. The TECNIS Odyssey combines advanced optics and proprietary materials, offering consistently clear, high-contrast vision, according to the company. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left ventricular ejection fraction (LVEF). Tempus ECG-Low EF joins Tempus ECG-AF as the second FDA-cleared ECG-AI device in Tempus' growing suite of next generation devices designed to identify patients at risk for a variety of cardiovascular conditions. "With Tempus ECG-Low EF, we're adding another powerful tool to the hands of clinicians to help them identify patients at risk for serious cardiovascular conditions much earlier in their care journey," said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. "Detection of LVEF is essential for undiagnosed patients, and this technology enables us to deliver that capability at scale to transform patient care. The addition of a second FDA-cleared Tempus ECG-AI solution reflects our continued commitment to advancing AI-driven cardiology." DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU was compensated forty nine hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements. Contact Information: Media Contact email: editor@ - +1(561)325-8757 View original content: SOURCE MarketNewsUpdates View original content: Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store